Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?

Journal of virology - 1 Jun 2001

Dix B R, Edwards S J, Braithwaite A W

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Mutation
Share to Neoplasms
Share to Tumor Cells, Cultured

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 11356950
DOI: 10.1128/JVI.75.12.5443-5447.2001
PMCID: PMC114255

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?PMID 11356950Read ↗

In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.Semantic proximity Read ↗

Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells.Semantic proximity Read ↗

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).Semantic proximity Read ↗

Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.Semantic proximity Read ↗

Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncologySemantic proximity Read ↗

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.Semantic proximity Read ↗

Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14 ARF Tumor Suppressor GenesSemantic proximity Read ↗

Advances in adenovirus-mediated p53 cancer gene therapySemantic proximity Read ↗

ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirusSemantic proximity Read ↗

Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumorsSemantic proximity Read ↗

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacySemantic proximity Read ↗

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.